IDT Australia lifts FY26 guidance as revenue climbs 16.5% to $16.8M
IDT Australia (ASX: IDT) has upgraded both its revenue and profit guidance for the financial year 2026 (FY26), citing favourable trading conditions and stronger operational performance.
The pharmaceutical manufacturer now expects unaudited revenue from its three verticals to rise 16.5% year-on-year to $16.8 million, with unaudited EBITDA improving to -$943K, compared with -$6.3M in FY25. That marks an 85.1% improvement in EBITDA.
The upgraded revenue figure sits above IDT’s previous guidance range of $15M to $16M. All figures remain unaudited and subject to audit, with full year audited results and a detailed outlook due next month, in August 2026.
When big ASX news breaks, our subscribers know first
Breaking down the upgraded numbers
The revision reflects a three-way beat across IDT’s headline metrics. Revenue from the company’s three verticals climbed to $16.8M, total revenue reached $20.3M (ahead of prior guidance of $18M to $19M), and the EBITDA loss narrowed sharply.
Disbursements rose modestly to $3.6M from the previous guidance of approximately $3M. On a year-on-year basis, however, disbursements are down 33.7%.
The full breakdown against FY25 actuals and prior guidance is set out below.
| Metric | FY25 Actual | Previous FY26 Guidance | New FY26 Guidance | % Chg YoY |
|---|---|---|---|---|
| Revenue from 3 verticals | $14.4M | $15M–$16M | $16.8M | +16.5% |
| Disbursements | $5.4M | ~$3M | $3.6M | -33.7% |
| Total revenue | $19.8M | $18M–$19M | $20.3M | +2.9% |
| EBITDA | -$6.3M | -$1.5M to -$2M | -$0.95M | +85.1% |
For investors, the standout figure is the EBITDA improvement. A loss narrowing from -$6.3M to a guided -$943K suggests IDT’s cost-out and transformation programme is delivering ahead of the company’s earlier expectations.
The trajectory visible in the H1 FY26 interim results, where the EBITDA loss had already narrowed 84% to $436K on the back of a 191% surge in API manufacturing revenue, established the foundation for the stronger full-year outcome now being guided.
What’s driving the upgrade
IDT attributed the revised guidance to two stated factors:
- Strong local and international demand momentum for IDT’s world-class facilities and end-to-end drug manufacturing services.
The Sanofi Preferred Vendor designation, secured earlier in 2026 following the companies’ mRNA vaccine collaboration, opened IDT’s pipeline to multiple Sanofi business units and contributed to the international demand momentum cited in today’s guidance upgrade.
- Cost savings running ahead of target.
The combination of top-line growth and improving cost control has narrowed the EBITDA loss considerably. While this points to a clear trajectory toward profitability, the company has not stated that it is currently profitable or cash-flow positive, and the guided EBITDA figure remains a loss.
Global recognition for IDT’s RNA capabilities
The company’s strategic transformation strategy received external acknowledgement from IMAPAC, an Asia Pacific biopharma research and networking organisation. At the Asia-Pacific RNA Excellence Awards 2026 in Singapore on 30 June 2026, IDT was presented with two awards:
-
Overall RNA Manufacturing Excellence Award
-
Best Emerging RNA CDMO Award
According to the announcement, the awards recognise the expertise, innovation, and dedication of IDT’s team in advancing RNA research, development, and manufacturing.
IDT Australia Announcement
“These awards acknowledge the expertise, innovation, and dedication of IDT’s team in advancing RNA research, development, and manufacturing. They also reinforce IDT’s growing leadership position in the rapidly expanding RNA therapeutics sector.”
Understanding the CDMO and RNA opportunity
For readers less familiar with the sector, a Contract Development and Manufacturing Organisation (CDMO) is a company that develops and manufactures pharmaceutical products on behalf of other drug companies. Rather than building their own facilities, pharmaceutical clients outsource this work to specialists such as IDT.
RNA therapeutics is a rapidly expanding area of medicine.
IDT’s facilities are cGMP compliant and are regularly audited by the US FDA and the Australian TGA.
For investors, this combination positions IDT within a high-growth therapeutic category, supported by regulatory credentials.
What comes next for investors
The near-term catalyst is the release of IDT’s full year audited results and detailed outlook, expected next month in August 2026. This report should confirm whether the unaudited guidance figures hold once the accounts are finalised.
The broader picture is one of revenue growth across three verticals paired with a sharp reduction in the EBITDA loss, pointing to an operational turnaround that appears to be gaining momentum. Investors should note, however, that all current figures remain subject to audit.
Key dates and watch-points include:
-
FY26 audited full-year results, expected August 2026
-
A detailed FY26 outlook to accompany those results
Is IDT Australia’s Operational Turnaround Gaining Real Momentum?
IDT Australia has upgraded its FY26 guidance across every key metric, with revenue from its three verticals climbing 16.5% to $16.8M and the EBITDA loss narrowing by 85.1% to -$943K. Dual RNA manufacturing awards from IMAPAC and a Sanofi Preferred Vendor designation further reinforce the company’s growing position in the high-growth RNA therapeutics sector.
Full-year audited results and a detailed outlook are expected in August 2026, offering investors the next material confirmation of this trajectory. Explore IDT Australia’s facilities, capabilities, and end-to-end drug manufacturing services at the IDT Australia official website.